Sellas Life Sciences has become a study in contrasts. The stock has surged nearly 900% from its November 2025 low, yet the company remains a pre-revenue biotech with no approved products. The rally reflects both a speculative wave and genuine anticipation for a pivotal cancer trial that is now tantalisingly close to completion.
The share price currently sits at €12.20, after a 1.24% gain on the day. Over the past twelve months, that represents a rise of roughly 645% — a figure that would turn heads even in the frothiest corners of the market. Yet the climb has not been smooth. Since hitting a 52-week high of €15.25 on 30 June 2026, the stock has given back 20% of its value. In the past week alone, it has shed nearly 7%.
The Trial That Holds the Key
At the heart of the story is REGAL, a Phase 3 study testing galinpepimut-S (GPS) as a maintenance therapy for patients with acute myeloid leukaemia in second complete remission. No approved maintenance therapy exists for this population, giving GPS a clear shot at an unmet medical need.
REGAL is an event-driven trial: its final analysis will be triggered only after 80 deaths among participants occur. As of 11 May 2026, that count stood at 78 — just two events short. The slow pace of accumulation has become a source of intense debate.
Chief Executive Angelos Stergiou argues that the delay could be a positive signal: patients may be living longer than initially modelled. He rejects the alternative explanation that improved standard therapies are to blame, noting that no such approved option exists for this group. Until the data are unblinded, neither interpretation can be verified — but the market is already pricing in a favourable outcome.
Retail Frenzy Meets Biotech Maths
The recent price action, however, is not purely a bet on the trial. The secondary article highlights a wave of buying activity tied to retail forums such as WallStreetBets, which drove the stock from single-digit territory to its June peak without any new data or partnerships. The primary article itself notes that the rally has pushed technical indicators into extreme territory.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
The current share price stands 59% above the 50-day moving average of €7.67 and fully 210% above the 200-day average of €3.94. The relative strength index sits at 65.9, edging towards overbought but not yet flashing a warning signal. Annualised 30-day volatility of around 125% underscores the wild swings — extreme even for a small-cap biotech.
A Financial Picture That Buys Time
Behind the speculative surface, Sellas has a workable cash runway. The company reported a net loss of $8.4 million in the first quarter of 2026. Yet it held approximately $107 million in cash and equivalents on its balance sheet, and recently raised an additional $7.5 million through exercised warrants. That should keep operations running for the foreseeable future without a dilutive capital raise.
Beyond GPS, Sellas is advancing a second asset: SLS009 (tambiciclib), a CDK9 inhibitor in a Phase 2 study for newly diagnosed AML patients. That programme has received scant attention amid the REGAL hype, but it could provide a secondary growth vector if GPS succeeds.
Analysts See Room — But Not Endless Room
Wall Street consensus points to a price target of €15.34, implying a 25.7% upside from current levels. That target roughly matches the stock’s recent high, suggesting analysts see a plausible path to that level but not a moonshot. The implied valuation of €2.33 billion rests entirely on future approval hopes — a binary setup that leaves little margin for error.
Two more trial events are all that separate Sellas from a data readout that could validate its story or deflate it entirely. Until then, the shares will remain a battlefield between retail speculators betting on momentum and institutional investors weighing the odds of a clinical success.
Ad
Sellas Life Sciences Stock: Buy or Sell?! New Sellas Life Sciences Analysis from July 9 delivers the answer:
The latest Sellas Life Sciences figures speak for themselves: Urgent action needed for Sellas Life Sciences investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 9.
Sellas Life Sciences: Buy or sell? Read more here...
